By Amy Norton
TUESDAY, May 12, 2020 (HealthDay News) — The coronavirus pandemic has affected all areas of medical care, and a new study finds it has delayed potentially life-saving organ transplants.
Across the United States, transplants from deceased donors dropped 51% from early March to early April, amid the COVID-19 outbreak, the researchers found. In France, meanwhile, those procedures plummeted 91%.
Experts said the findings, published online May 11 in The Lancet, come as no surprise.
The figures, they said, largely reflect efforts to protect patients, and to deal with the diversion of hospital resources to COVID-19.
Much of the decrease was in kidney transplants, partly because they are the most common organ transplant. But it’s also because people with advanced kidney disease can be maintained on dialysis while they await a donor organ, explained Dr. David Klassen, chief medical officer for the United Network for Organ Sharing (UNOS).
So there is generally less urgency around a kidney transplant, compared to a heart, liver or lung transplant, Klassen said.
UNOS is a nonprofit that manages the U.S. organ transplantation system. The new findings are based on its data, but it did not conduct the study.
“Transplants in the U.S. have not shut down,” Klassen said. “But, clearly, we want to do them as safely as possible.”
Dr. Peter Reese, an associate professor of medicine at the University of Pennsylvania in Philadelphia, was part of the study team.
“The good news is, we’ve carried on through the worst of COVID-19,” he said. However, Reese added, while some transplants can be delayed, patients on waiting lists for donor organs undoubtedly missed out on opportunities.
“The tragedy is, there were deceased-donor organs that patients did not receive, and that we’ll never get back,” he said.
Right now, more than 112,000 Americans are on the waitlist for a donor organ, according to UNOS. More than 94,000 of them need a kidney. And while kidney patients can receive dialysis, it doesn’t always buy the time they need: Each year, around 9,000 patients on the waitlist either die or have to be removed from the queue due to worsening health.
When COVID-19 hit the United States, most transplants from living donors — which can be rescheduled — were put on temporary hold. One reason was to protect donors from possible exposure to the virus in the hospital, Klassen said.
Transplant patients also require many hospital resources, including intensive care beds. If a living donor is involved, that means two patients for each procedure.
And at the start of the outbreak, U.S. transplant centers did not know whether every city was going to “look like New York,” said Dr. Stephen Pastan, medical director of the kidney and pancreas transplant program at Emory University in Atlanta.
“Hospitals were preparing for the worst,” said Pastan, who is also a board member of the National Kidney Foundation.
“At Emory,” he noted, “we took a cautious approach and closed our kidney program.”
It also took time, nationally, for testing protocols to be put in place. Transplant recipients need to be tested for coronavirus infection, Pastan said, to ensure they don’t bring it into the hospital.
Meanwhile, organ procurement organizations started testing donors for the virus, according to the American Society of Transplantation.
Now, Pastan said, “programs are slowly ramping up again.”
The current study, which looked at data through April 10, does not capture more recent trends. According to Klassen, of UNOS, there has been no indication of further declines in U.S. transplants.
The decrease across U.S. centers, while significant, was less stark than the 91% drop in France.
Pastan said that likely reflects the difference in health care systems: In the United States, individual transplant centers decided what to do — which, to Pastan, is a good thing, since the outbreak has not been uniform across the country.
Reese made a similar point.
“There was no dress rehearsal for COVID,” he said. “But now it’s obvious the prevalence of infection across the country is heterogeneous. We’re coming around to the idea there can be some customization, depending on where the transplant center is.”
Even in areas with few COVID-19 cases, safety concerns remain.
One is whether organ recipients could be at greater risk of severe coronavirus infection soon after a transplant — when regimens to suppress the immune system, and avoid organ rejection, would be strongest.
At this point, Pastan said, there is no proof that’s the case. But, he added, transplant patients should “assume that they are at increased risk,” and follow all recommended precautions to avoid exposure to the virus.
Copyright © 2020 HealthDay. All rights reserved.
What is the Wuhan coronavirus?
SOURCES: Peter Reese, M.D., associate professor of medicine and epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia; David Klassen, M.D., chief medical officer, United Network for Organ Sharing, Richmond, Va.; Stephen Pastan, M.D., professor of medicine, and medical director, Kidney and Pancreas Transplant Program, Emory University School of Medicine, Atlanta, and board member, National Kidney Foundation, New York City; May 11, 2020, The Lancet, online
Subscribe to our Newsletter and get the complete health program for a health you.